ROCO
4157
Market cap208mUSD
Oct 08, Last price
9.33TWD
1D
9.12%
1Q
2.19%
Jan 2017
-65.70%
IPO
-71.32%
Name
Taigen Biopharmaceuticals Holdings Ltd
Chart & performance
P/E
147.01
P/S
25.60
EPS
0.06
Div yield, %
—
Shrs. gr., 5y
-0.02%
Rev. gr., 5y
61.77%
Revenues
259m
+72.24%
Net income
45m
P
CFO
21m
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm dedicated to pioneering innovative treatments for life-altering diseases. Its robust development pipeline features several key assets. Among these is Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic currently being advanced for the treatment of various bacterial infections, including community-acquired pneumonia and diabetic foot infections. The company is also progressing Burixafor, a stem cell mobilizer with applications in stem cell transplantation and chemosensitization. Further contributing to its portfolio is TG-1000, an antiviral medication designed to combat influenza A, B, and the avian influenza H7N9 strain. Additionally, Furaprevir, a hepatitis C virus (HCV) protease inhibitor, is under development for managing chronic hepatitis C. Established in 2001, TaiGen Biopharmaceuticals maintains its headquarters in Taipei City, Taiwan.
Key people
Li-Wen Chang
Deputy General Manager-Clinical Development Division · since 2019
Richard Lu
Deputy General Manager-Finance and Administration Division, Corporate Governance Officer · since 2021
Cheng-Yuan Tsai
Deputy General Manager-Preclinical Research Division · since 2020
Mark Kao
Head of Accounting · since 2019
Director · since 2010
Director · since 2013
Chi-Kung Ho
Director · since 2022
I-Jen Huang
Director · since 2023
Kuo-Lung Huang
Chairman of the Board, Chief Executive Officer, General Manager · since 2019
Peter Wu
Director · since 2022
Independent Director · since 2011
Independent Director · since 2019
Independent Director · since 2025
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||